Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-341

Hi,

Correct me if I'm wrong but as I understand it, the data is saying this:
1. At albuminuria level of > 500mg/mol = reduction of 18%. (Out of the 40, 26 people had 500mg/mol or higher)
2. Out of the 26, 64% had a reduction of 25% or more in albuminuria level.
3. Across the whole population tested (40), no significant difference between placebo and dmx-200. The reason being both placebo and dmx reduced albuminuria levels. dmx200 showed a reduction of 14% and placebo a reduction of 12% hence no significant difference. Hence, more data is needed to know about legacy effect and why the placebo did good things (-12%).

Data needs some understanding but a careful reading should ease the worries. Management is simply trying to tell us that the result is statistically significant at albuminuria level of 500mg/mmol. Just have to get more data to explain why the placebo also worked. Make no mistake, it's a placebo. If a placebo could do magic like that, we don't need to figure out this disease.

Check the presentation slides and the announcement for confirmation.

Stay cool holders..
- Potential downside will be independent from the results e.g. if any hindrances on REMAP results etc.
- IMO there is plenty of upside.
- Sure it could slide some more if markets keep dropping, but im a happy camper holding.

Can't wait for more explanation. Not many biotech companies at this value going into Phase 3 studies.